5 active not recruiting, 5 recruiting, 4 completed, 1 withdrawn. 8 Phase 1, 7 Phase 2, 2 Early Phase 1, 2 Phase 3.
Follow Unresectable Gastroesophageal Junction Adenocarcinoma: new trials by email Literature Review of Unresectable Gastroesophageal Junction Adenocarcinoma trials Research Report on Unresectable Gastroesophageal Junction Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors Azenosertib, Biopsy Procedure, Biospecimen Collection - Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 48 | 2025-02-03 | 2026-10-19 |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 224 | 2024-06-24 | 2026-10-23 |
| A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer AgenT-797, Botensilimab, Balstilimab - Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2024-02-01 | 2026-05-15 |
| Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma Biopsy, Biospecimen Collection, Computed Tomography - Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Phase 2 | Recruiting | Roswell Park Cancer Institute | 40 | 2023-03-07 | 2025-12-16 |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma Fluorouracil, Leucovorin Calcium, Oxaliplatin - Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 382 | 2023-01-31 | 2026-10-02 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma Lenvatinib, Pembrolizumab - Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2022-02-14 | 2026-07-16 |
| Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery Carboplatin, Paclitaxel, Radiation Therapy - Advanced Esophageal Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Phase 1 | Active not recruiting | NRG Oncology | 16 | 2021-12-02 | 2026-10-01 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Biopsy Procedure, Biospecimen Collection, Ceralasertib - Advanced Breast Carcinoma, Advanced Colon Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 51 | 2021-08-09 | 2026-09-04 |
| Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers Adavosertib, Radiation Therapy - Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 4 | 2021-04-09 | 2026-07-31 |
| Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer Berzosertib, Computed Tomography Assisted Biopsy, Endoscopic Biopsy - Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2020-11-16 | 2026-10-20 |
| Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer Docetaxel, Fluorouracil, Oxaliplatin - Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 1 | Completed | M.D. Anderson Cancer Center | 16 | 2020-09-16 | 2026-08-13 |
| MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Liposomal Irinotecan, Quality-of-Life Assessment, Questionnaire Administration - Locally Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | Withdrawn | University of Southern California | 2020-04-06 | 2020-03-27 | |
| Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma Pembrolizumab - Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 9 | 2018-02-09 | 2023-11-18 |
| Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery Olaparib, Ramucirumab - Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 51 | 2018-02-06 | 2026-02-03 |
Adenocarcinoma Of Esophagus (5) · Stomach Neoplasms (4) · Neoplasm Metastasis (3) · Carcinosarcoma (2) · Endometrial Neoplasms (2) · Esophageal Neoplasms (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Lobular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1)
Neoplasms (7) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Neoplasms by Site (6) · Gastrointestinal Diseases (5) · Gastrointestinal Neoplasms (5) · Head and Neck Neoplasms (5) · Neoplasms by Histologic Type (4) · Stomach Diseases (4) · Carcinoma (3) · Esophageal Diseases (3) · Neoplasms, Glandular and Epithelial (3) · Neoplastic Processes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3)
Magnetic Resonance Spectroscopy (6) · Biopsy (5) · Specimen Handling (5) · pembrolizumab (5) · Ramucirumab (4) · Fluorouracil (3) · Oxaliplatin (3) · Paclitaxel (3) · Radiation (3) · Radiotherapy (3) · dehydroftorafur (3) · Irinotecan (2) · Leucovorin (2) · Nivolumab (2) · Taxes (2)
National Cancer Institute (NCI) (6) · M.D. Anderson Cancer Center (3) · Alliance for Clinical Trials in Oncology (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · NRG Oncology (1) · Roswell Park Cancer Institute (1) · University of Southern California (1)
United States (15) · Puerto Rico (1)
Jaffer A Ajani (2) · Afsaneh Barzi, MD (1) · Anwaar Saeed (1) · Eric D Miller (1) · Funda Meric-Bernstam (1) · Geoffrey Y Ku (1) · Jordan D Berlin (1) · Kannan Thanikachalam (1) · Kanwal P Raghav (1) · Mariela Blum (1) · Michael Cecchini (1) · Yanyan Lou, MD, PhD (1) · Yelena Janjigian, MD (1)
UM1CA186688 (2), UM1CA186689 (2), P30CA014089 (1), U10CA180868 (1), U10CA180888 (1), UM1CA186712 (1)